ZA964733B - Ob protein compositions and methods - Google Patents

Ob protein compositions and methods

Info

Publication number
ZA964733B
ZA964733B ZA964733A ZA964733A ZA964733B ZA 964733 B ZA964733 B ZA 964733B ZA 964733 A ZA964733 A ZA 964733A ZA 964733 A ZA964733 A ZA 964733A ZA 964733 B ZA964733 B ZA 964733B
Authority
ZA
South Africa
Prior art keywords
methods
protein compositions
protein
compositions
Prior art date
Application number
ZA964733A
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Michael Benjamin Mann
Randy HECHT
Original Assignee
Amgen Inc A Legal Body Organis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc A Legal Body Organis filed Critical Amgen Inc A Legal Body Organis
Publication of ZA964733B publication Critical patent/ZA964733B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA964733A 1995-06-07 1996-06-06 Ob protein compositions and methods ZA964733B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47483395A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ZA964733B true ZA964733B (en) 1997-01-07

Family

ID=23885121

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA964733A ZA964733B (en) 1995-06-07 1996-06-06 Ob protein compositions and methods

Country Status (6)

Country Link
US (3) US20020009798A1 (xx)
EP (1) EP0832220A1 (xx)
AU (1) AU6028396A (xx)
CA (1) CA2223433C (xx)
WO (1) WO1996040912A1 (xx)
ZA (1) ZA964733B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ES2093593T1 (es) * 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
CA2281888A1 (en) * 1997-02-25 1998-08-27 Eli Lilly And Company Treatment of infertility with leptin receptor ligands
AU6569998A (en) * 1997-03-20 1998-10-12 Eli Lilly And Company Obesity protein formulations
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
US7838619B2 (en) 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2004009774A2 (en) 2002-07-19 2004-01-29 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
WO2004009082A1 (en) 2002-07-19 2004-01-29 The General Hospital Corporation Oxime conjugates and methods for their formation and use
SI21273A (sl) * 2002-07-31 2004-02-29 LEK farmacevtska dru�ba d.d. Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
ES2365918T3 (es) 2003-09-05 2011-10-13 The General Hospital Corporation Conjugados de poliacetal-fármaco como sistema de liberación.
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
CA2560289A1 (en) * 2004-03-23 2005-10-13 Amgen Inc. Chemically modified protein compositions and methods
US20080319862A1 (en) * 2004-08-10 2008-12-25 Hiromedia Ltd. Method and system for preventing ad stripping from ad-supported digital content
US20060036488A1 (en) * 2004-08-10 2006-02-16 Hiro-Media Ltd. Method and system for dynamic, real-time addition of advertisements to downloaded static content
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
CA2618068C (en) * 2005-08-05 2016-02-16 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2010022262A2 (en) * 2008-08-20 2010-02-25 The Board Of Regents Of The University Of Texas System Methods for treating type i diabetes with leptin and leptin agonists
PA8853201A1 (es) 2008-12-10 2010-07-27 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables
WO2011005488A1 (en) 2009-06-22 2011-01-13 Amgen Inc. Refolding proteins using a chemically controlled redox state
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
EP2621519B1 (en) 2010-09-28 2017-06-28 Aegerion Pharmaceuticals, Inc. Leptin-abd fusion polypeptides with enhanced duration of action
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0719860B1 (en) 1988-05-13 2009-12-16 Amgen Inc. Process for isolating and purifying G-CSF
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
ZA924674B (en) 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) * 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods

Also Published As

Publication number Publication date
US20020009798A1 (en) 2002-01-24
CA2223433A1 (en) 1996-12-19
EP0832220A1 (en) 1998-04-01
WO1996040912A1 (en) 1996-12-19
US20090082275A1 (en) 2009-03-26
US7524940B2 (en) 2009-04-28
CA2223433C (en) 2003-11-18
AU6028396A (en) 1996-12-30
US20030054997A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
ZA964733B (en) Ob protein compositions and methods
HK1021388A1 (en) Ob fusion protein compositions and methods
GB9616411D0 (en) Shampoo compositions and method
AU4008495A (en) Tcl-1 gene and protein and related methods and compositions
HUP9900743A3 (en) Bituminous composition and using them
AU7237496A (en) Methods and compositions comprising single chain recombinant antibodies
HUP0100535A3 (en) Hydrophobically-modified protein compositions and methods
ZA9684B (en) Composition and use
EP0758531A3 (en) Compositions of fat-free or low-fat mayonnaise
GB2298713B (en) Method and composition
PL321935A1 (en) Electroplating compositions and methods
GB9510830D0 (en) Proteins
HUP0000280A3 (en) Canine ob protein compositions and methods
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
GB9423372D0 (en) Proteins and their uses
HUP9601885A2 (en) Injection composition and injection suspension
GB9519865D0 (en) Protein
AU1468797A (en) Ghrh-rp compositions and methods
GB9523843D0 (en) Cosmetic composition and method
GB9622436D0 (en) Protein
AU2003204051A1 (en) OB Protein Compositions and Method
GB9512703D0 (en) Composition and use
SI0877803T1 (sl) Receptor ob-proteina in sorodni sestavki in postopki
AU706700C (en) N-terminally chemically modified protein compositions and methods
GB9503315D0 (en) Composition and method